{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
telotristat ethyl
to a specific field?
Status:
Investigational
Source:
NCT01779427: Not Applicable Interventional Withdrawn Traumatic Brain Injury (TBI)
(2013)
Source URL:
Class (Stereo):
CHEMICAL (RACEMIC)
Status:
Investigational
Source:
INN:brezivaptan [INN]
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Status:
Investigational
Source:
NCT03527212: Phase 3 Interventional Completed Dry Eye Syndromes
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Senju Pharmaceutical is developing fonadelpar (also known as SJP-0035), a peroxisome proliferator activated receptor delta agonist as an ophthalmic solution. Fonadelpar was studied in phase III clinical trial in the USA for the treatment of patients with dry eye disease. This study was successfully completed. In addition, fonadelpar was involved in phase II clinical trial in the USA for the treatment of patients with moderate to severe corneal epithelial disorders. Besides, Senju Pharmaceutical also plans a phase II trial for corneal disorders in Japan.
Status:
Investigational
Source:
NCT01027234: Phase 1 Interventional Terminated Healthy
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT03218826: Phase 1 Interventional Active, not recruiting Advanced Breast Carcinoma
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
AZD-8186 is a potent and selective inhibitor of PI3Kβ and PI3Kδ with IC50 of 4 nM and 12 nM, respectively. AZD-8186 is currently in phase 1 clinical trials. Combination therapy using AZD-8186 with androgen deprivation results in long-lasting tumor regression, which persisted after treatment cessation.
Status:
Investigational
Source:
NCT03327519: Not Applicable Interventional Terminated Asthma
(2018)
Source URL:
Class (Stereo):
CHEMICAL (MIXED)
Status:
Investigational
Source:
NCT04488081: Phase 2 Interventional Recruiting COVID-19
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT03563599: Phase 2 Interventional Completed Treatment-naïve, Sputum Smear-positive Patients With Drug-sensitive Pulmonary TB
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Q203 (6-chloro-2-ethyl-N-(4-(4-(4-(trifluoromethoxy)phenyl)piperidin-1-yl)benzyl)imidazo [1,2-a]pyridine-3-carboxamide) is an an imidazopyridine antitubercular
compound. Q203 targets the cytochrome b subunit (QcrB) of the cytochrome bc1 complex. This complex is an essential component of the respiratory electron transport chain of ATP synthesis. Q203 inhibited the growth of multidrug-resistant (MDR) and extensively drug-resistant (XDR) M. tuberculosis clinical isolates in culture broth medium in the low nanomolar range and was efficacious in a mouse model of tuberculosis at a dose less than 1 mg per kg body weight, which highlights the potency of this compound. In addition, Q203 displays pharmacokinetic and safety profiles compatible with once-daily dosing. Q203 is a promising new clinical candidate for the treatment of tuberculosis.
Status:
Investigational
Source:
INN:idrevloride [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT02977780: Phase 2 Interventional Recruiting Glioblastoma
(2017)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
CC-115 is a recently identified inhibitor of the mammalian Target of Rapamycin Kinase (TORK) and DNA-Dependent Protein Kinase (DNA-PK). It is under investigation in phase II clinical trials for the treatment for Glioblastoma and in phase I trials for the treatment of prostate cancer, Ewing's, Osteosarcoma, Chronic Lymphocytic Leukemia and Squamous Cell Carcinoma of the Head and Neck.
